CROSSROADS STRATEGIES, LLC
Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · represents biopharmaceutical research companies
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals; Section 301 tariffs.